CINECA IRIS Institutional Research Information System

NOVELLO, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.470
AS - Asia 21.679
EU - Europa 20.794
SA - Sud America 1.281
OC - Oceania 704
AF - Africa 393
Continente sconosciuto - Info sul continente non disponibili 241
Totale 73.562
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.165
CN - Cina 9.748
IT - Italia 4.789
GB - Regno Unito 2.716
JP - Giappone 2.716
SG - Singapore 2.625
DE - Germania 2.154
IE - Irlanda 1.673
FR - Francia 1.639
IN - India 1.456
ES - Italia 1.098
SE - Svezia 1.081
KR - Corea 1.067
CA - Canada 1.038
HK - Hong Kong 819
BR - Brasile 818
NL - Olanda 742
VN - Vietnam 717
PL - Polonia 689
FI - Finlandia 626
AU - Australia 614
UA - Ucraina 554
TW - Taiwan 538
AT - Austria 534
CH - Svizzera 486
TR - Turchia 453
BE - Belgio 362
ID - Indonesia 350
RU - Federazione Russa 254
IL - Israele 235
DK - Danimarca 218
PT - Portogallo 209
MX - Messico 199
TH - Thailandia 197
GR - Grecia 186
RO - Romania 144
IR - Iran 130
AP - ???statistics.table.value.countryCode.AP??? 129
AR - Argentina 118
MY - Malesia 116
CZ - Repubblica Ceca 108
NO - Norvegia 108
CO - Colombia 106
PE - Perù 105
ZA - Sudafrica 102
EU - Europa 96
NZ - Nuova Zelanda 89
HU - Ungheria 87
PH - Filippine 86
EG - Egitto 73
PK - Pakistan 71
SA - Arabia Saudita 66
CL - Cile 65
JO - Giordania 59
RS - Serbia 52
MA - Marocco 47
BG - Bulgaria 37
SI - Slovenia 35
HR - Croazia 34
LT - Lituania 33
NG - Nigeria 32
EC - Ecuador 31
MK - Macedonia 26
SK - Slovacchia (Repubblica Slovacca) 26
BD - Bangladesh 25
IQ - Iraq 23
TN - Tunisia 23
DZ - Algeria 21
CY - Cipro 20
UY - Uruguay 20
LB - Libano 18
MO - Macao, regione amministrativa speciale della Cina 18
UZ - Uzbekistan 18
AE - Emirati Arabi Uniti 17
BY - Bielorussia 17
BA - Bosnia-Erzegovina 15
CR - Costa Rica 15
DO - Repubblica Dominicana 15
AM - Armenia 14
ET - Etiopia 14
LV - Lettonia 14
SN - Senegal 13
KZ - Kazakistan 12
VE - Venezuela 12
CU - Cuba 11
GH - Ghana 11
MT - Malta 11
EE - Estonia 10
LY - Libia 10
UG - Uganda 10
LK - Sri Lanka 9
PA - Panama 9
XK - ???statistics.table.value.countryCode.XK??? 9
TJ - Tagikistan 8
AZ - Azerbaigian 7
GE - Georgia 7
AL - Albania 6
GT - Guatemala 6
KE - Kenya 6
MD - Moldavia 6
Totale 73.456
Salva come PNG Salva come JPEG
Città #
Beijing 2.227
Dublin 1.623
Chandler 1.583
Santa Clara 1.522
Singapore 1.498
Fairfield 1.444
Houston 1.346
Redwood City 1.139
Shanghai 1.125
Woodbridge 856
Ashburn 850
Torino 848
Wilmington 781
Tokyo 704
Duncan 660
Ann Arbor 655
Seattle 636
Turin 565
Cambridge 539
Guangzhou 538
Princeton 527
Columbus 473
New York 469
Medford 467
Pisa 427
London 411
Hangzhou 405
Vienna 398
Nanjing 394
Warsaw 357
Villeurbanne 354
Taipei 349
Jacksonville 343
Nyköping 342
Dong Ket 297
Chengdu 290
Milan 282
Jakarta 281
Boston 255
Dearborn 245
Fremont 245
Jinan 244
Madrid 226
Seoul 226
Amsterdam 215
Zhengzhou 208
Los Angeles 205
Toronto 195
Wuhan 184
San Diego 181
Sydney 169
Mumbai 165
Paris 162
Chicago 159
Hong Kong 157
Rome 156
Changsha 155
Düsseldorf 155
São Paulo 148
Central 140
Ottawa 137
Nuremberg 132
Barcelona 131
Brussels 131
Munich 131
Manchester 126
Philadelphia 124
Tianjin 119
Frankfurt am Main 117
Hyderabad 117
Central District 114
Shenyang 114
Helsinki 113
Boardman 112
Hefei 110
Nutley 108
Osaka 105
Berlin 100
Hebei 100
Zurich 99
Bengaluru 98
Chongqing 98
Hanoi 96
San Jose 94
Fuzhou 93
Jerusalem 93
Silver Spring 93
Atlanta 92
San Francisco 88
Norwalk 84
Delhi 81
Chennai 79
Kunming 78
Bangkok 73
Xian 72
Lima 71
Nanchang 71
Pune 71
Collegeville 69
Ho Chi Minh City 69
Totale 36.203
Salva come PNG Salva come JPEG
Nome #
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer 10.753
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer 5.032
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. 4.080
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. 3.740
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2.125
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study 1.769
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer 1.725
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s 1.327
Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer 855
Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial 853
PARP inhibitors: an interesting pathway also for non-small cell lung cancer? 748
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial 670
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis 656
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer 558
Extending survival of stage IV non-small cell lung cancer. 550
Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled lume-meso trial 492
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 480
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 469
Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer? 456
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry 451
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. 438
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario 395
Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: A prospective study 391
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial 390
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. Results from a multicenter Italian observational study 375
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 349
Detection of EGFR mutations in archival lung cancer samples by pyrosequencing 334
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with non-adenocarcinoma non-small cell lung cancer. 330
Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study 328
Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer 327
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations 320
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 317
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. 315
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. 303
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma 290
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. 282
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 278
Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report 273
The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. 269
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. 258
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. 250
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 250
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker 236
Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study 233
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 232
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. 221
ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. 214
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018 209
Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer 198
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. 197
Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research. 190
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing 187
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin 184
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer 183
Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 173
Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. 170
Epidermal growth factor receptor tyrosine kinase inhibitors as adjuvant therapy in completely resected non-small-cell lung cancer 170
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer 157
Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer 155
Fetal adenocarcinoma of the lung in a 25-year-old woman 154
Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers 153
Fatigue in lung cancer patients: symptom burden and management of challenges. 152
Clinical and biological significance of CD157 in malignant pleural mesothelioma 150
Current state-of-the-art therapy for advanced squamous cell lung cancer 146
Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. 145
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 145
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer 144
Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. 144
Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib. 141
Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer 140
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study 137
Thymidylate synthase expression in large cell carcinoma ofthe lung 136
Accuracy of CT-guided transthoracic needle biopsy of lung lesions: Factors affecting diagnostic yield 134
Tackling ALK in non-small cell lung cancer: The role of novel inhibitors 134
Clonal Heterogeneity in Non-Small Cell Lung Cancer and the Possible Role in Predicting Response to Treatment with Immune Checkpoint Inhibitors 134
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer 132
Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era 132
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 132
IκBα targeting promotes oxidative stress-dependent cell death 132
Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey 131
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients 129
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Apr 29 128
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival 127
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung 126
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study 125
Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion 124
Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma 124
Diagnostica per immagini 123
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. 122
Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases 122
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine 120
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study 120
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 120
First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era 119
Trattamento del carcinoma polmonare in stadio avanzato. Dall’approccio classico alla medicina di precisione e prospettive future. 118
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 118
Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study 117
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer: A Phase-II Study. 117
SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer 116
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. 114
Totale 53.537
Salva come PNG Salva come JPEG
Categoria #
all - tutte 170.680
article - articoli 0
book - libri 0
conference - conferenze 5.874
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 176.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.005 0 0 0 0 0 0 0 0 0 721 698 586
2020/202111.991 583 623 911 960 1.156 1.079 901 947 1.144 1.151 979 1.557
2021/202211.605 946 892 901 959 882 780 996 895 836 830 1.364 1.324
2022/202310.785 930 788 522 923 878 1.925 895 893 1.075 520 766 670
2023/20249.372 996 1.090 713 786 733 773 869 884 181 742 741 864
2024/202510.521 544 1.132 832 1.304 2.462 1.177 705 793 1.520 52 0 0
Totale 75.827